Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Genedrive Plc LSE:GDR London Ordinary Share GB00B1VKB244 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 2.91% 53.00 52.00 54.00 54.50 51.00 51.50 413,492 15:32:37
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.1 -20.4 -55.0 - 30

Genedrive PLC PHE National Framework Agreement

19/04/2021 7:00am

UK Regulatory (RNS & others)


Genedrive (LSE:GDR)
Historical Stock Chart


From Jan 2021 to Jul 2021

Click Here for more Genedrive Charts.

TIDMGDR

RNS Number : 8068V

Genedrive PLC

19 April 2021

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS DEFINED IN REGULATION (EU) NO 596/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL OF 16 APRIL 2014 ON MARKET ABUSE (MARKET ABUSE REGULATION) AS RETAINED AS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED.

genedrive plc

("genedrive" or the "Company")

Genedrive successful in PHE National Framework Agreement for Diagnostics Goods and Services

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces it has been successful with its tender into Public Health England ("PHE") under Lot 1 of the National Microbiology Framework (Diagnostic Goods and Services).

The PHE tender was opened in November 2020 and sought to appoint suppliers to a multi-lot national microbiology framework agreement relating to the supply of Diagnostics Goods and Services and covering Clinical Laboratory Diagnostic Testing Services.

The award of a framework contract is not exclusive to the Company, nor a guarantee of orders, however it does allow participating authorities to issue call-off orders for products in the future. All of genedrive's currently available and CE marked products fall within the framework agreement: Genedrive(R) 96 SARS-CoV-2 Kit, Genedrive(R) HCV ID Kit, Genedrive(R) MT-RNR1 ID Kit

David Budd, CEO of genedrive plc, said: "We are very pleased to have received notice of this contract award decision and look forward to the opportunity to engage with PHE and relevant authorities on future potential contracts. This is an early notification of the decision and we will update shareholders when we have more information on what this contract may mean for orders and revenues".

For further details please contact:

 
 genedrive plc                                                                 +44 (0)161 989 0245 
 David Budd: CEO / Matthew Fowler: 
  CFO 
 
 Peel Hunt LLP (Nominated Adviser 
  and Joint Broker)                                                            +44 (0)20 7418 8900 
 James Steel / Victoria Erskine 
 
            finnCap (Joint Broker)                                             +44 (0)20 7220 0500 
            Geoff Nash / Kate Bannatyne / Alice 
             Lane 
 
 Walbrook PR Ltd (Media & Investor                 +44 (0)20 7933 8780 or genedrive@walbrookpr.com 
  Relations) 
                                                                 +44 (0)7980 541 893 / +44 (0)7876 
 Paul McManus / Anna Dunphy                                                                741 001 
 

About genedrive plc ( http://www.genedriveplc.com )

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive(R) Point of Care version of the assay, both based on Genedrive(R) chemistry.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

AGRBRGDSRXBDGBI

(END) Dow Jones Newswires

April 19, 2021 02:00 ET (06:00 GMT)

1 Year Genedrive Chart

1 Year Genedrive Chart

1 Month Genedrive Chart

1 Month Genedrive Chart
ADVFN Advertorial
Your Recent History
LSE
GDR
Genedrive
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210725 18:49:56